Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Get Free Report)’s stock price traded down 4% during trading on Thursday after ...

Study results support the role of functional dystrophin and suggest that delandistrogene moxeparvovec stabilizes or slows ...

Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report)‘s stock had its “buy” rating reissued by equities research analysts at ...

Avidity Biosciences Inc. says will submit an application for accelerated approval to the FDA for del-zota before the end of ...

A patient has died while receiving Elevidys, a gene therapy for Duchenne muscular dystrophy, marking the first known death ...

Precision BioSciences (DTIL) announced the presentation of preclinical data for its PBGENE-DMD development program for the treatment of ...

A young person with Duchenne muscular dystrophy died following treatment with the recently approved gene therapy ...

The company plans to submit a biologics licence application to the US Food and Drug Administration later this year.

After some earlier data sparked questions from analysts, Avidity Biosciences has released more data for its RNA-based ...

Dyne is eyeing an accelerated approval filing for DYNE-251 in early 2026 that would pit the asset against Sarepta’s Exondys ...

The Phase I/II Deliver trial sought to establish the impact of DYNE-251 on several mobility-related endpoints, seeing an ...

Italfarmaco S.p.A. today announced a comprehensive update on the regulatory and clinical advancements for givinostat, the company’s drug for the treat ...